ICER on MS drugs: TG's ubli­tux­imab not cost ef­fec­tive at the same price as Roche's ocre­lizum­ab

Drug pric­ing watch­dog ICER keeps its eye on what price point a drug is best suit­ed for based on clin­i­cal ben­e­fit — and the group’s newest draft re­port takes a clos­er look at MS treat­ments com­pared to a new one await­ing the FDA’s fi­nal say.

The watch­dog fo­cused on TG Ther­a­peu­tics’ new, po­ten­tial block­buster ubli­tux­imab, which is pend­ing FDA re­view, and com­pared it to oth­er class­es of dis­ease-mod­i­fy­ing ther­a­pies (DMTs, as ICER calls them) that are cur­rent­ly on the mar­ket.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN